The National Institute for Health and Care Excellence

Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars

We’re delighted that NICE has approved bevacizumab for first- and second-line treatment in combination with chemotherapy for advanced bowel cancer patients in England and Wales, following a similar ...
The National Institute for Health and Care Excellence

NICE announces Professor Jonathan Benger CBE as new chief executive

NICE Chairman, Sharmila Nebhrajani, today announced Professor Jonathan Benger CBE as incoming chief executive, with effect from Friday 19 December 2025 taking over from Dr Samantha Roberts.
National Institute for Health and Care Excellence

Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency

Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma TA1113 3 December 2025 3 December 2025 Talquetamab for treating relapsed and refractory ...
National Institute for Health and Care Excellence

In consultation: Guidance and quality standards

Lifileucel for previously treated unresectable or metastatic melanoma ID3863 Draft guidance Technology appraisal guidance 22 January 2026 Filgotinib for treating axial spondyloarthritis ID6594 ...
National Institute for Health and Care Excellence

Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

Suggested remit: To appraise the clinical and cost effectiveness of givinostat within its marketing authorisation for treating Duchenne muscular dystrophy in people 6 years and over. Anticipate the ...
National Institute for Health and Care Excellence

COVID-19 rapid guideline: severe asthma

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our ...
National Institute for Health and Care Excellence

Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment

We have moved health technology evaluation 12 to become HealthTech guidance 696. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme ...
National Institute for Health and Care Excellence

Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer

This guidance has been updated and replaced by osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer ...
National Institute for Health and Care Excellence

Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

Isatuximab, plus pomalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults who have had ...
National Institute for Health and Care Excellence

Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...